Replies to post #44872 on CV Sciences Inc (CVSI)

[MaxwellE]

Good post Marty, you old rockin' roller. Before reading your post, I had just commented to my fiancé that CVSI has had a number of positive articles written in the last couple of weeks, forecasting a reversal of fortune. I think I can speak for all longs when I say, I am more than ready for it...M

[playofthedivine]

MT: Most excellent overview!

"We are in the right stock at the right time with the right brand and the right leadership team and the right financials and the right brand loyalty and the right legal CBD market. That's a whole lot of rights there.

Love your reference to John McClain in Die Hard. I especially love the scene where he says one of the most famous lines in movie history: "Yipee Yi Kay M______ker!"

The doubters say: "Who are you CVSI? Just another diluting OTC machine? Do you really think you have a chance against the FDA, the pharmaceuticals behemoths?"

The longs say: "Yippe ki yay . . . . . . "

Here's the scene of Hans Gruber talking to McClane:

"You know my name, but who are you? Just another American who saw too many movies as a child? Another orphan of a bankrupt culture who thinks he's John Wayne? Rambo? Marshal Dillon?"

"I was always kind of partial to Roy Rogers, actually. I really like those sequined shirts."

"Do you really think you have a chance against us, Mr. Cowboy?"

"Yippee-Ki-Yay, mother______!"

Hans then mockingly uses the line before McClane kills him at the climax of the film.

The CBD Hemp market is bigger than most projections going out 3, 4, 5 years.

"According to Brightfield Group, the hemp CBD market will reach $591 million this year (2018). And by 2022, it will soar to $22 billion. That is a five-year compound annual growth rate of 132% and a 40-bagger!

. . . we’re looking at an industry with the potential to be 55 times larger in just five years.

. . . In 2018, there were zero sales of hemp-derived CBD products at major chain retailers. By 2022, Brightfield Group believes sales at chain retailers will be nearly $14 billion and make up 67% of the $22 billion hemp-derived CBD market in the U.S."

"CBD is the most promising drug that has come out for neuropsychiatric diseases in the last 50 years,” said Dr. Esther Blessing, an assistant professor at New York University School of Medicine, who is coordinating a study of CBD as a treatment for post-traumatic stress disorder and alcohol use disorder. “The reason it is so promising is that it has a unique combination of safety and effectiveness across of very broad range of conditions.”